{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:15:34Z","timestamp":1789676134858,"version":"4.0.1"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02864-5","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:55:07Z","timestamp":1751565307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Therapeutic frontiers in adrenocortical carcinoma: from standards to innovation"],"prefix":"10.1007","volume":"42","author":[{"given":"Dylan M.","family":"Schaap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily X.","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton G.","family":"Mayberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Braydon C.","family":"Cowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"issue":"8","key":"2864_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.14740\/jocmr3503w","volume":"10","author":"E Sharma","year":"2018","unstructured":"Sharma E, Dahal S, Sharma P, et al. The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018;10(8):636\u201340. https:\/\/doi.org\/10.14740\/jocmr3503w.","journal-title":"J Clin Med Res"},{"issue":"4","key":"2864_CR2","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1\u201346. https:\/\/doi.org\/10.1530\/EJE-18-0608.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2864_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.surg.2018.04.068","volume":"165","author":"JA Glenn","year":"2019","unstructured":"Glenn JA, Else T, Hughes DT, et al. Longitudinal patterns of recurrence in patients with adrenocortical carcinoma. Surgery. 2019;165(1):186\u201395. https:\/\/doi.org\/10.1016\/j.surg.2018.04.068.","journal-title":"Surgery"},{"issue":"11","key":"2864_CR4","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1016\/j.ejca.2013.02.034","volume":"49","author":"TM Kerkhofs","year":"2013","unstructured":"Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49(11):2579\u201386. https:\/\/doi.org\/10.1016\/j.ejca.2013.02.034.","journal-title":"Eur J Cancer"},{"issue":"7","key":"2864_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cncr.31916","volume":"125","author":"T Chandrasekar","year":"2019","unstructured":"Chandrasekar T, Goldberg H, Klaassen Z, et al. The who, when, and why of primary adrenal malignancies: insights into the epidemiology of a rare clinical entity. Cancer. 2019;125(7):1050\u20139. https:\/\/doi.org\/10.1002\/cncr.31916.","journal-title":"Cancer"},{"key":"2864_CR6","doi-asserted-by":"publisher","unstructured":"Puglisi S, Calabrese A, Ferra\u00f9 F, et al. New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study [published correction appears in J Clin Endocrinol Metab. 2024;109(5):e1420. https:\/\/doi.org\/10.1210\/clinem\/dgae063]. J Clin Endocrinol Metab. 2023;108(10):2517\u20132525. https:\/\/doi.org\/10.1210\/clinem\/dgad199.","DOI":"10.1210\/clinem\/dgae063"},{"issue":"6","key":"2864_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1530\/EC-20-0196","volume":"9","author":"JS Lim","year":"2020","unstructured":"Lim JS, Lee SE, Kim JH, Kim JH. Characteristics of adrenocortical carcinoma in South Korea: a registry-based nationwide survey. Endocr Connect. 2020;9(6):519\u201329. https:\/\/doi.org\/10.1530\/EC-20-0196.","journal-title":"Endocr Connect"},{"issue":"9","key":"2864_CR8","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/oncolo\/oyae029","volume":"29","author":"D Chukkalore","year":"2024","unstructured":"Chukkalore D, MacDougall K, Master V, Bilen MA, Nazha B. Adrenocortical carcinomas: molecular pathogenesis, treatment options, and emerging immunotherapy and targeted therapy approaches. Oncologist. 2024;29(9):738\u201346. https:\/\/doi.org\/10.1093\/oncolo\/oyae029.","journal-title":"Oncologist"},{"issue":"1","key":"2864_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13053-024-00276-6","volume":"22","author":"A Ohmoto","year":"2024","unstructured":"Ohmoto A, Hayashi N, Takahashi S, Ueki A. Current prospects of hereditary adrenal tumors: towards better clinical management. Hered Cancer Clin Pract. 2024;22(1):4. https:\/\/doi.org\/10.1186\/s13053-024-00276-6.","journal-title":"Hered Cancer Clin Pract"},{"issue":"1","key":"2864_CR10","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.surg.2019.04.066","volume":"167","author":"A Sada","year":"2020","unstructured":"Sada A, Asaad M, Bews KA, et al. Comparison between functional and non-functional adrenocortical carcinoma. Surgery. 2020;167(1):216\u201323. https:\/\/doi.org\/10.1016\/j.surg.2019.04.066.","journal-title":"Surgery"},{"issue":"2","key":"2864_CR11","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35(2):282\u2013326. https:\/\/doi.org\/10.1210\/er.2013-1029.","journal-title":"Endocr Rev"},{"issue":"2","key":"2864_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ecl.2015.02.007","volume":"44","author":"Y Nakamura","year":"2015","unstructured":"Nakamura Y, Yamazaki Y, Felizola SJ, et al. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis. Endocrinol Metab Clin N Am. 2015;44(2):399\u2013410. https:\/\/doi.org\/10.1016\/j.ecl.2015.02.007.","journal-title":"Endocrinol Metab Clin N Am"},{"key":"2864_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100759","volume":"37","author":"R Lib\u00e9","year":"2023","unstructured":"Lib\u00e9 R, Huillard O. Adrenocortical carcinoma: Diagnosis, prognostic classification and treatment of localized and advanced disease. Cancer Treat Res Commun. 2023;37: 100759. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100759.","journal-title":"Cancer Treat Res Commun"},{"issue":"11","key":"2864_CR14","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","volume":"26","author":"K Kiseljak-Vassiliades","year":"2020","unstructured":"Kiseljak-Vassiliades K, Bancos I, Hamrahian A, et al. American Association of Clinical Endocrinology Disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach. Endocr Pract. 2020;26(11):1366\u201383. https:\/\/doi.org\/10.4158\/DSCR-2020-0567.","journal-title":"Endocr Pract"},{"issue":"4","key":"2864_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.suc.2019.04.012","volume":"99","author":"SE Long","year":"2019","unstructured":"Long SE, Miller BS. Adrenocortical cancer treatment. Surg Clin N Am. 2019;99(4):759\u201371. https:\/\/doi.org\/10.1016\/j.suc.2019.04.012.","journal-title":"Surg Clin N Am"},{"issue":"10","key":"2864_CR16","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","volume":"157","author":"L Yip","year":"2022","unstructured":"Yip L, Duh QY, Wachtel H, et al. American association of endocrine surgeons guidelines for adrenalectomy: executive summary. JAMA Surg. 2022;157(10):870\u20137. https:\/\/doi.org\/10.1001\/jamasurg.2022.3544.","journal-title":"JAMA Surg"},{"issue":"5","key":"2864_CR17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.jviscsurg.2017.06.010","volume":"154","author":"S Gaujoux","year":"2017","unstructured":"Gaujoux S, Weinandt M, Bonnet S, Reslinger V, Bertherat J, Dousset B. Surgical treatment of adrenal carcinoma. J Visc Surg. 2017;154(5):335\u201343. https:\/\/doi.org\/10.1016\/j.jviscsurg.2017.06.010.","journal-title":"J Visc Surg"},{"issue":"3","key":"2864_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101408","volume":"34","author":"TJ Sinclair","year":"2020","unstructured":"Sinclair TJ, Gillis A, Alobuia WM, Wild H, Kebebew E. Surgery for adrenocortical carcinoma: when and how? Best Pract Res Clin Endocrinol Metab. 2020;34(3): 101408. https:\/\/doi.org\/10.1016\/j.beem.2020.101408.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"5","key":"2864_CR19","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1245\/s10434-018-6398-5","volume":"25","author":"KL Anderson Jr","year":"2018","unstructured":"Anderson KL Jr, Adam MA, Thomas SM, et al. Impact of micro- and macroscopically positive surgical margins on survival after resection of adrenocortical carcinoma. Ann Surg Oncol. 2018;25(5):1425\u201331. https:\/\/doi.org\/10.1245\/s10434-018-6398-5.","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"2864_CR20","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.3390\/jcm11195754","volume":"11","author":"L Rossi","year":"2022","unstructured":"Rossi L, Becucci C, Ambrosini CE, et al. Surgical management of adrenocortical carcinoma: a literature review. J Clin Med. 2022;11(19):5754. https:\/\/doi.org\/10.3390\/jcm11195754.","journal-title":"J Clin Med"},{"issue":"2","key":"2864_CR21","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1245\/s10434-022-12711-w","volume":"30","author":"H Nakanishi","year":"2023","unstructured":"Nakanishi H, Miangul S, Wang R, et al. Open versus laparoscopic surgery in the management of adrenocortical carcinoma: a systematic review and meta-analysis. Ann Surg Oncol. 2023;30(2):994\u20131005. https:\/\/doi.org\/10.1245\/s10434-022-12711-w.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2864_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1530\/EJE-09-1096","volume":"162","author":"S Leboulleux","year":"2010","unstructured":"Leboulleux S, Deandreis D, Al Ghuzlan A, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010;162(6):1147\u201353. https:\/\/doi.org\/10.1530\/EJE-09-1096.","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2864_CR23","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1007\/s00464-013-3034-0","volume":"27","author":"AB Cooper","year":"2013","unstructured":"Cooper AB, Habra MA, Grubbs EG, et al. Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma? Surg Endosc. 2013;27(11):4026\u201332. https:\/\/doi.org\/10.1007\/s00464-013-3034-0.","journal-title":"Surg Endosc"},{"issue":"5","key":"2864_CR24","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.21037\/tau.2020.01.11","volume":"10","author":"DM Buller","year":"2021","unstructured":"Buller DM, Hennessey AM, Ristau BT. Open versus minimally invasive surgery for suspected adrenocortical carcinoma. Transl Androl Urol. 2021;10(5):2246\u201363. https:\/\/doi.org\/10.21037\/tau.2020.01.11.","journal-title":"Transl Androl Urol"},{"key":"2864_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jss.2022.04.078","volume":"279","author":"AM Delman","year":"2022","unstructured":"Delman AM, Turner KM, Griffith A, Schepers E, Ammann AM, Holm TM. Minimally invasive surgery for resectable adrenocortical carcinoma: a nationwide analysis. J Surg Res. 2022;279:200\u20137. https:\/\/doi.org\/10.1016\/j.jss.2022.04.078.","journal-title":"J Surg Res"},{"issue":"1","key":"2864_CR26","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023;189(1):G1\u201342. https:\/\/doi.org\/10.1093\/ejendo\/lvad066.","journal-title":"Eur J Endocrinol"},{"key":"2864_CR27","doi-asserted-by":"publisher","unstructured":"Langenhuijsen J, Birtle A, Klatte T, Porpiglia F, Timsit MO. Surgical management of adrenocortical carcinoma: impact of laparoscopic approach, lymphadenectomy, and surgical volume on outcomes-a systematic review and meta-analysis of the current literature [published correction appears in Eur Urol Focus. 2018;4(3):461. https:\/\/doi.org\/10.1016\/j.euf.2016.04.001]. Eur Urol Focus. 2016;1(3):241\u201350. https:\/\/doi.org\/10.1016\/j.euf.2015.12.001.","DOI":"10.1016\/j.euf.2016.04.001"},{"issue":"3","key":"2864_CR28","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1245\/s10434-021-11051-5","volume":"29","author":"J Tseng","year":"2022","unstructured":"Tseng J, DiPeri T, Chen Y, et al. Adrenocortical carcinoma: the value of lymphadenectomy. Ann Surg Oncol. 2022;29(3):1965\u201370. https:\/\/doi.org\/10.1245\/s10434-021-11051-5.","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"2864_CR29","doi-asserted-by":"publisher","first-page":"291","DOI":"10.3390\/cancers14020291","volume":"14","author":"A Hendricks","year":"2022","unstructured":"Hendricks A, M\u00fcller S, Fassnacht M, et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma\u2014a systematic review and meta-analysis. Cancers (Basel). 2022;14(2):291. https:\/\/doi.org\/10.3390\/cancers14020291.","journal-title":"Cancers (Basel)"},{"key":"2864_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(24)00378-4","author":"M Fassnacht","year":"2025","unstructured":"Fassnacht M, Puglisi S, Kimpel O, Terzolo M. Adrenocortical carcinoma: a practical guide for clinicians. Lancet Diabetes Endocrinol. 2025. https:\/\/doi.org\/10.1016\/S2213-8587(24)00378-4.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"2864_CR31","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.clgc.2021.03.009","volume":"19","author":"JJ Thomas","year":"2021","unstructured":"Thomas JJ, Tward JD. Stage presentation, care patterns, treatment outcomes, and impact of radiotherapy on overall survival for adrenocortical carcinoma. Clin Genitourin Cancer. 2021;19(5):417\u201324. https:\/\/doi.org\/10.1016\/j.clgc.2021.03.009.","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2864_CR32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1097\/PPO.0b013e31829e3221","volume":"19","author":"J Ho","year":"2013","unstructured":"Ho J, Turkbey B, Edgerly M, et al. Role of radiotherapy in adrenocortical carcinoma. Cancer J. 2013;19(4):288\u201394. https:\/\/doi.org\/10.1097\/PPO.0b013e31829e3221.","journal-title":"Cancer J"},{"key":"2864_CR33","doi-asserted-by":"publisher","first-page":"1308231","DOI":"10.3389\/fendo.2023.1308231","volume":"14","author":"L Wu","year":"2024","unstructured":"Wu L, Chen J, Su T, et al. Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma. Front Endocrinol (Lausanne). 2024;14:1308231. https:\/\/doi.org\/10.3389\/fendo.2023.1308231.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"2864_CR34","doi-asserted-by":"publisher","first-page":"791.e1","DOI":"10.1016\/j.urolonc.2021.06.019","volume":"39","author":"KB Ginsburg","year":"2021","unstructured":"Ginsburg KB, Chandra AA, Schober JP, et al. Identification of oncological characteristics associated with improved overall survival in patients with adrenocortical carcinoma treated with adjuvant radiation therapy: Insights from the National Cancer Database. Urol Oncol. 2021;39(11):791.e1-791.e7. https:\/\/doi.org\/10.1016\/j.urolonc.2021.06.019.","journal-title":"Urol Oncol"},{"key":"2864_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2025.116194","volume":"242","author":"BC Greenspun","year":"2025","unstructured":"Greenspun BC, Lee-Saxton YJ, Egan CE, et al. Adjuvant radiation therapy is not associated with a survival benefit after R0 resection in non-metastatic adrenocortical carcinoma. Am J Surg. 2025;242: 116194. https:\/\/doi.org\/10.1016\/j.amjsurg.2025.116194.","journal-title":"Am J Surg"},{"issue":"4","key":"2864_CR36","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41416-022-02082-0","volume":"128","author":"O Kimpel","year":"2023","unstructured":"Kimpel O, Schindler P, Schmidt-Pennington L, et al. Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma. Br J Cancer. 2023;128(4):586\u201393. https:\/\/doi.org\/10.1038\/s41416-022-02082-0.","journal-title":"Br J Cancer"},{"issue":"6","key":"2864_CR37","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s002800050610","volume":"39","author":"W Cai","year":"1997","unstructured":"Cai W, Counsell RE, Schteingart DE, Sinsheimer JE, Vaz AD, Wotring LL. Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemother Pharmacol. 1997;39(6):537\u201340. https:\/\/doi.org\/10.1007\/s002800050610.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"2864_CR38","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1210\/jcem.87.3.8281","volume":"87","author":"O Lindhe","year":"2002","unstructured":"Lindhe O, Skogseid B, Brandt I. Cytochrome P450-catalyzed binding of 3-methylsulfonyl-DDE and o,p\u2019-DDD in human adrenal zona fasciculata\/reticularis. J Clin Endocrinol Metab. 2002;87(3):1319\u201326. https:\/\/doi.org\/10.1210\/jcem.87.3.8281.","journal-title":"J Clin Endocrinol Metab"},{"key":"2864_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.117917","volume":"184","author":"A Schiavon","year":"2025","unstructured":"Schiavon A, Saba L, Evaristo C, et al. Mitotane activates ATF4\/ATF3 axis triggering endoplasmic reticulum stress in adrenocortical carcinoma cells. Biomed Pharmacother. 2025;184: 117917. https:\/\/doi.org\/10.1016\/j.biopha.2025.117917.","journal-title":"Biomed Pharmacother"},{"issue":"21","key":"2864_CR40","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.3390\/cancers13215255","volume":"13","author":"M Lo Iacono","year":"2021","unstructured":"Lo Iacono M, Puglisi S, Perotti P, et al. Molecular mechanisms of mitotane action in adrenocortical cancer based on in vitro studies. Cancers (Basel). 2021;13(21):5255. https:\/\/doi.org\/10.3390\/cancers13215255.","journal-title":"Cancers (Basel)"},{"issue":"66","key":"2864_CR41","doi-asserted-by":"publisher","first-page":"109924","DOI":"10.18632\/oncotarget.18968","volume":"8","author":"S Hescot","year":"2017","unstructured":"Hescot S, Amazit L, Lhomme M, et al. Identifying mitotane-induced mitochondria-associated membranes dysfunctions: metabolomic and lipidomic approaches. Oncotarget. 2017;8(66):109924\u201340. https:\/\/doi.org\/10.18632\/oncotarget.18968.","journal-title":"Oncotarget"},{"issue":"23","key":"2864_CR42","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356(23):2372\u201380. https:\/\/doi.org\/10.1056\/NEJMoa063360.","journal-title":"N Engl J Med"},{"issue":"1","key":"2864_CR43","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1677\/ERC-09-0190","volume":"17","author":"B Wangberg","year":"2010","unstructured":"Wangberg B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer. 2010;17(1):265\u201372. https:\/\/doi.org\/10.1677\/ERC-09-0190.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"2864_CR44","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and adrenal tumors, version 22021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2021;19(7):839\u201368. https:\/\/doi.org\/10.6004\/jnccn.2021.0032.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"4","key":"2864_CR45","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1210\/jc.2016-2894","volume":"102","author":"A Berruti","year":"2017","unstructured":"Berruti A, Grisanti S, Pulzer A, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab. 2017;102(4):1358\u201365. https:\/\/doi.org\/10.1210\/jc.2016-2894.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2864_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1210\/jc.2013-2856","volume":"99","author":"T Else","year":"2014","unstructured":"Else T, Williams AR, Sabolch A, Jolly S, Miller BS, Hammer GD. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99(2):455\u201361. https:\/\/doi.org\/10.1210\/jc.2013-2856.","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2864_CR47","doi-asserted-by":"publisher","first-page":"A166","DOI":"10.1210\/jendso\/bvab048.336","volume":"5","author":"M Terzolo","year":"2021","unstructured":"Terzolo M, Fassnacht M, Perotti P, et al. Results of the ADIUVO study, the first randomized trial on adjuvant mitotane in adrenocortical carcinoma patients. J Endocr Soc. 2021;5(Suppl 1):A166\u20137. https:\/\/doi.org\/10.1210\/jendso\/bvab048.336.","journal-title":"J Endocr Soc"},{"issue":"6","key":"2864_CR48","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::aid-cncr1461>3.0.co;2-2","volume":"92","author":"E Baudin","year":"2001","unstructured":"Baudin E, Pellegriti G, Bonnay M, et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001;92(6):1385\u201392. https:\/\/doi.org\/10.1002\/1097-0142(20010915)92:6%3c1385::aid-cncr1461%3e3.0.co;2-2.","journal-title":"Cancer"},{"issue":"9","key":"2864_CR49","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1634\/theoncologist.2016-0459","volume":"22","author":"DL Reidy-Lagunes","year":"2017","unstructured":"Reidy-Lagunes DL, Lung B, Untch BR, et al. Complete responses to mitotane in metastatic adrenocortical carcinoma\u2014a new look at an old drug. Oncologist. 2017;22(9):1102\u20136. https:\/\/doi.org\/10.1634\/theoncologist.2016-0459.","journal-title":"Oncologist"},{"issue":"7","key":"2864_CR50","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s00268-001-0047-y","volume":"25","author":"P Icard","year":"2001","unstructured":"Icard P, Goudet P, Charpenay C, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001;25(7):891\u20137. https:\/\/doi.org\/10.1007\/s00268-001-0047-y.","journal-title":"World J Surg"},{"issue":"23","key":"2864_CR51","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189\u201397. https:\/\/doi.org\/10.1056\/NEJMoa1200966.","journal-title":"N Engl J Med"},{"issue":"10","key":"2864_CR52","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2194::AID-CNCR19>3.0.CO;2-3","volume":"83","author":"A Berruti","year":"1998","unstructured":"Berruti A, Terzolo M, Pia A, Angeli A, Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998;83(10):2194\u2013200.","journal-title":"Cancer"},{"issue":"9","key":"2864_CR53","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/cncr.10487","volume":"94","author":"J Abraham","year":"2002","unstructured":"Abraham J, Bakke S, Rutt A, et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer. 2002;94(9):2333\u201343. https:\/\/doi.org\/10.1002\/cncr.10487.","journal-title":"Cancer"},{"issue":"5","key":"2864_CR54","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","volume":"75","author":"M Kroiss","year":"2011","unstructured":"Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2011;75(5):585\u201391. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04214.x.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2864_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092615","author":"V Basile","year":"2020","unstructured":"Basile V, Puglisi S, Calabrese A, et al. Unwanted hormonal and metabolic effects of postoperative adjuvant mitotane treatment for adrenocortical cancer. Cancers (Basel). 2020. https:\/\/doi.org\/10.3390\/cancers12092615.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2864_CR56","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1530\/EJE-17-0452","volume":"177","author":"G Reimondo","year":"2017","unstructured":"Reimondo G, Puglisi S, Zaggia B, et al. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. Eur J Endocrinol. 2017;177(4):361\u20137. https:\/\/doi.org\/10.1530\/EJE-17-0452.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2864_CR57","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.path.2019.08.010","volume":"12","author":"A Vaidya","year":"2019","unstructured":"Vaidya A, Nehs M, Kilbridge K. Treatment of adrenocortical carcinoma. Surg Pathol Clin. 2019;12(4):997\u20131006. https:\/\/doi.org\/10.1016\/j.path.2019.08.010.","journal-title":"Surg Pathol Clin"},{"key":"2864_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13195001","author":"M Bianchini","year":"2021","unstructured":"Bianchini M, Puliani G, Chiefari A, Mormando M, Lauretta R, Appetecchia M. Metabolic and endocrine toxicities of mitotane: a systematic review. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13195001.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2864_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cen.14345","volume":"94","author":"ME Vikner","year":"2021","unstructured":"Vikner ME, Krogh J, Daugaard G, Andreassen M. Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: a retrospective study in 50 Danish patients. Clin Endocrinol (Oxf). 2021;94(2):141\u20139. https:\/\/doi.org\/10.1111\/cen.14345.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2864_CR60","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1093\/oncolo\/oyae084","volume":"29","author":"J Del Rivero","year":"2024","unstructured":"Del Rivero J, Else T, Hallanger-Johnson J, et al. A review of mitotane in the management of adrenocortical cancer. Oncologist. 2024;29(9):747\u201360. https:\/\/doi.org\/10.1093\/oncolo\/oyae084.","journal-title":"Oncologist"},{"issue":"3","key":"2864_CR61","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/00007611-198603000-00037","volume":"79","author":"PG Cuddy","year":"1986","unstructured":"Cuddy PG, Loftus LS. Influence of mitotane on the hypoprothrombinemic effect of warfarin. South Med J. 1986;79(3):387\u20138. https:\/\/doi.org\/10.1097\/00007611-198603000-00037.","journal-title":"South Med J"},{"issue":"1","key":"2864_CR62","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1210\/jc.2012-2851","volume":"98","author":"V Chortis","year":"2013","unstructured":"Chortis V, Taylor AE, Schneider P, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5\u03b1-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab. 2013;98(1):161\u201371. https:\/\/doi.org\/10.1210\/jc.2012-2851.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2864_CR63","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2265.1989.tb00453.x","volume":"31","author":"RV Hague","year":"1989","unstructured":"Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p\u2019DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf). 1989;31(1):51\u20137. https:\/\/doi.org\/10.1111\/j.1365-2265.1989.tb00453.x.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"2864_CR64","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17925\/EE.2018.14.2.62","volume":"14","author":"RM Paragliola","year":"2018","unstructured":"Paragliola RM, Torino F, Papi G, Locantore P, Pontecorvi A, Corsello SM. Role of mitotane in adrenocortical carcinoma\u2014review and state of the art. Eur Endocrinol. 2018;14(2):62\u20136. https:\/\/doi.org\/10.17925\/EE.2018.14.2.62.","journal-title":"Eur Endocrinol"},{"issue":"3","key":"2864_CR65","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1530\/EJE-13-0242","volume":"169","author":"M Terzolo","year":"2013","unstructured":"Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169(3):263\u201370. https:\/\/doi.org\/10.1530\/EJE-13-0242.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2864_CR66","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1677\/ERC-08-0103","volume":"15","author":"F Daffara","year":"2008","unstructured":"Daffara F, De Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;15(4):1043\u201353. https:\/\/doi.org\/10.1677\/ERC-08-0103.","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2864_CR67","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-12-0358","volume":"167","author":"C Baudry","year":"2012","unstructured":"Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing\u2019s disease in 76 patients from a single center. Eur J Endocrinol. 2012;167(4):473\u201381. https:\/\/doi.org\/10.1530\/EJE-12-0358.","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2864_CR68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40262-020-00913-y","volume":"60","author":"A Yin","year":"2021","unstructured":"Yin A, Ettaieb MHT, Swen JJ, et al. Population pharmacokinetic and pharmacogenetic analysis of mitotane in patients with adrenocortical carcinoma: towards individualized dosing. Clin Pharmacokinet. 2021;60(1):89\u2013102. https:\/\/doi.org\/10.1007\/s40262-020-00913-y.","journal-title":"Clin Pharmacokinet"},{"key":"2864_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/life11030266","author":"S Allegra","year":"2021","unstructured":"Allegra S, Puglisi S, Brescia I, et al. Sex differences on mitotane concentration and treatment outcome in patients with adrenocortical carcinoma. Life (Basel). 2021. https:\/\/doi.org\/10.3390\/life11030266.","journal-title":"Life (Basel)"},{"issue":"2","key":"2864_CR70","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1677\/ERC-09-0281","volume":"17","author":"P Sperone","year":"2010","unstructured":"Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-\/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17(2):445\u201353. https:\/\/doi.org\/10.1677\/ERC-09-0281.","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2864_CR71","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1210\/jc.2017-01624","volume":"102","author":"JEK Henning","year":"2017","unstructured":"Henning JEK, Deutschbein T, Altieri B, et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J Clin Endocrinol Metab. 2017;102(11):4323\u201332. https:\/\/doi.org\/10.1210\/jc.2017-01624.","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2864_CR72","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166(3):451\u20138. https:\/\/doi.org\/10.1530\/EJE-11-0918.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2864_CR73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s12672-016-0260-7","volume":"7","author":"M Kroiss","year":"2016","unstructured":"Kroiss M, Deutschbein T, Schlotelburg W, et al. Salvage treatment of adrenocortical carcinoma with trofosfamide. Horm Cancer. 2016;7(3):211\u20138. https:\/\/doi.org\/10.1007\/s12672-016-0260-7.","journal-title":"Horm Cancer"},{"issue":"3","key":"2864_CR74","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3275\/8334","volume":"36","author":"A Ferrero","year":"2013","unstructured":"Ferrero A, Sperone P, Ardito A, et al. Metronomic chemotherapy may be active in heavily pre-treated patients with metastatic adreno-cortical carcinoma. J Endocrinol Invest. 2013;36(3):148\u201352. https:\/\/doi.org\/10.3275\/8334.","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"2864_CR75","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1055\/a-0747-5571","volume":"127","author":"M Kroiss","year":"2019","unstructured":"Kroiss M, Deutschbein T, Schlotelburg W, et al. Treatment of refractory adrenocortical carcinoma with thalidomide: analysis of 27 patients from the european network for the study of adrenal tumours registry. Exp Clin Endocrinol Diabetes. 2019;127(9):578\u201384. https:\/\/doi.org\/10.1055\/a-0747-5571.","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"11","key":"2864_CR76","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1210\/js.2018-00197","volume":"2","author":"DR Mohan","year":"2018","unstructured":"Mohan DR, Lerario AM, Hammer GD. Therapeutic targets for adrenocortical carcinoma in the genomics era. J Endocr Soc. 2018;2(11):1259\u201374. https:\/\/doi.org\/10.1210\/js.2018-00197.","journal-title":"J Endocr Soc"},{"key":"2864_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102283","volume":"80","author":"KP Burke","year":"2023","unstructured":"Burke KP, Patterson DG, Liang D, Sharpe AH. Immune checkpoint receptors in autoimmunity. Curr Opin Immunol. 2023;80: 102283. https:\/\/doi.org\/10.1016\/j.coi.2023.102283.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"2864_CR78","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1210\/clinem\/dgae109","volume":"109","author":"LS Landwehr","year":"2024","unstructured":"Landwehr LS, Altieri B, Sbiera I, et al. Expression and prognostic relevance of PD-1, PD-L1, and CTLA-4 immune checkpoints in adrenocortical carcinoma. J Clin Endocrinol Metab. 2024;109(9):2325\u201334. https:\/\/doi.org\/10.1210\/clinem\/dgae109.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2864_CR79","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.3390\/cancers13112660","volume":"13","author":"GJ Pegna","year":"2021","unstructured":"Pegna GJ, Roper N, Kaplan RN, et al. The immunotherapy landscape in adrenocortical cancer. Cancers (Basel). 2021;13(11):2660. https:\/\/doi.org\/10.3390\/cancers13112660.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2864_CR80","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/biomedicines9020098","volume":"9","author":"I Karwacka","year":"2021","unstructured":"Karwacka I, Obo\u0142o\u0144czyk \u0141, Kaniuka-Jakubowska S, Sworczak K. The role of immunotherapy in the treatment of adrenocortical carcinoma. Biomedicines. 2021;9(2):98. https:\/\/doi.org\/10.3390\/biomedicines9020098.","journal-title":"Biomedicines"},{"issue":"5","key":"2864_CR81","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/cancers16050900","volume":"16","author":"O Ababneh","year":"2024","unstructured":"Ababneh O, Ghazou A, Alawajneh M, et al. The efficacy and safety of immune checkpoint inhibitors in adrenocortical carcinoma: a systematic review and meta-analysis. Cancers (Basel). 2024;16(5):900. https:\/\/doi.org\/10.3390\/cancers16050900.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2864_CR82","doi-asserted-by":"publisher","first-page":"6193","DOI":"10.1210\/jc.2019-00600","volume":"104","author":"BA Carneiro","year":"2019","unstructured":"Carneiro BA, Konda B, Costa RB, et al. Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial. J Clin Endocrinol Metab. 2019;104(12):6193\u2013200. https:\/\/doi.org\/10.1210\/jc.2019-00600.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2864_CR83","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","volume":"6","author":"C Le Tourneau","year":"2018","unstructured":"Le Tourneau C, Hoimes C, Zarwan C, et al. Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. J Immunother Cancer. 2018;6(1):111. https:\/\/doi.org\/10.1186\/s40425-018-0424-9.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2864_CR84","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","volume":"7","author":"MA Habra","year":"2019","unstructured":"Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019;7(1):253. https:\/\/doi.org\/10.1186\/s40425-019-0722-x.","journal-title":"J Immunother Cancer"},{"key":"2864_CR85","doi-asserted-by":"publisher","unstructured":"Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers [published correction appears in J Immunother Cancer. 2020;8(1):e000347corr1. https:\/\/doi.org\/10.1136\/jitc-2019-000347corr1]. J Immunother Cancer. 2020;8(1):e000347. https:\/\/doi.org\/10.1136\/jitc-2019-000347.","DOI":"10.1136\/jitc-2019-000347corr1"},{"issue":"1","key":"2864_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","volume":"38","author":"N Raj","year":"2020","unstructured":"Raj N, Zheng Y, Kelly V, et al. PD-1 blockade in advanced adrenocortical carcinoma. J Clin Oncol. 2020;38(1):71\u201380. https:\/\/doi.org\/10.1200\/JCO.19.01586.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2864_CR87","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12964-025-02115-0","volume":"23","author":"R Catalano","year":"2025","unstructured":"Catalano R, Nozza E, Altieri B, et al. Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas. Cell Commun Signal. 2025;23(1):119. https:\/\/doi.org\/10.1186\/s12964-025-02115-0.","journal-title":"Cell Commun Signal"},{"issue":"3","key":"2864_CR88","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12020-019-01869-1","volume":"64","author":"MC De Martino","year":"2019","unstructured":"De Martino MC, van Koetsveld PM, Feelders RA, et al. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. Endocrine. 2019;64(3):673\u201384. https:\/\/doi.org\/10.1007\/s12020-019-01869-1.","journal-title":"Endocrine"},{"issue":"4","key":"2864_CR89","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/bjc.2013.46","volume":"108","author":"A Naing","year":"2013","unstructured":"Naing A, LoRusso P, Fu S, et al. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma. Br J Cancer. 2013;108(4):826\u201330. https:\/\/doi.org\/10.1038\/bjc.2013.46.","journal-title":"Br J Cancer"},{"issue":"4","key":"2864_CR90","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s12672-014-0182-1","volume":"5","author":"AM Lerario","year":"2014","unstructured":"Lerario AM, Worden FP, Ramm CA, et al. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent\/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. Hormones Cancer. 2014;5(4):232\u20139. https:\/\/doi.org\/10.1007\/s12672-014-0182-1.","journal-title":"Hormones Cancer"},{"issue":"4","key":"2864_CR91","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/S1470-2045(15)70081-1","volume":"16","author":"M Fassnacht","year":"2015","unstructured":"Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16(4):426\u201335. https:\/\/doi.org\/10.1016\/S1470-2045(15)70081-1.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2864_CR92","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/ejendo\/lvad054","volume":"188","author":"H Remde","year":"2023","unstructured":"Remde H, Schmidt-Pennington L, Reuter M, et al. Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort study. Eur J Endocrinol. 2023;188(6):485\u201393. https:\/\/doi.org\/10.1093\/ejendo\/lvad054.","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2864_CR93","doi-asserted-by":"publisher","first-page":"e220273","DOI":"10.1530\/ERC-22-0273","volume":"30","author":"A Abate","year":"2022","unstructured":"Abate A, Tamburello M, Rossini E, et al. Trabectedin impairs invasiveness and metastasis in adrenocortical carcinoma preclinical models. Endocr Relat Cancer. 2022;30(2):e220273. https:\/\/doi.org\/10.1530\/ERC-22-0273.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2864_CR94","doi-asserted-by":"publisher","first-page":"187585922413084","DOI":"10.1177\/18758592241308440","volume":"42","author":"S Li","year":"2025","unstructured":"Li S, Xiao S, Situ Y. Apolipoprotein C1 and apoprotein E as potential therapeutic and prognostic targets for adrenocortical carcinoma. Cancer Biomark. 2025;42(1):18758592241308440. https:\/\/doi.org\/10.1177\/18758592241308440.","journal-title":"Cancer Biomark"},{"issue":"2","key":"2864_CR95","doi-asserted-by":"publisher","first-page":"bqab248","DOI":"10.1210\/endocr\/bqab248","volume":"163","author":"A Abate","year":"2022","unstructured":"Abate A, Rossini E, Tamburello M, et al. Ribociclib cytotoxicity alone or combined with progesterone and\/or mitotane in in vitro adrenocortical carcinoma cells. Endocrinology. 2022;163(2):bqab248. https:\/\/doi.org\/10.1210\/endocr\/bqab248.","journal-title":"Endocrinology"},{"issue":"1","key":"2864_CR96","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13046-022-02464-5","volume":"41","author":"D Laha","year":"2022","unstructured":"Laha D, Grant RRC, Mishra P, et al. Preclinical assessment of synergistic efficacy of MELK and CDK inhibitors in adrenocortical cancer. J Exp Clin Cancer Res. 2022;41(1):282. https:\/\/doi.org\/10.1186\/s13046-022-02464-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"2864_CR97","doi-asserted-by":"publisher","first-page":"878365","DOI":"10.3389\/fimmu.2022.878365","volume":"13","author":"KM Knudson","year":"2022","unstructured":"Knudson KM, Hwang S, McCann MS, Joshi BH, Husain SR, Puri RK. Recent advances in IL-13R\u03b12-directed cancer immunotherapy. Front Immunol. 2022;13:878365. https:\/\/doi.org\/10.3389\/fimmu.2022.878365.","journal-title":"Front Immunol"},{"issue":"1","key":"2864_CR98","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/ph17010025","volume":"17","author":"K Michalski","year":"2023","unstructured":"Michalski K, Schl\u00f6telburg W, Hartrampf PE, et al. Radiopharmaceuticals for treatment of adrenocortical carcinoma. Pharmaceuticals (Basel). 2023;17(1):25. https:\/\/doi.org\/10.3390\/ph17010025.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2864_CR99","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.213496","author":"GP Nicolas","year":"2018","unstructured":"Nicolas GP, Morgenstern A, Schottelius M, Fani M. New developments in peptide receptor radionuclide therapy. J Nucl Med. 2018. https:\/\/doi.org\/10.2967\/jnumed.118.213496.","journal-title":"J Nucl Med"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02864-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02864-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02864-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:43:36Z","timestamp":1757205816000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02864-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":99,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["2864"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02864-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Use of AI tools declaration"}}],"article-number":"311"}}